The Market Access Biosimilars 2020 symposium, organised by Forum-Institut für Management, will deal with the changes in the German biosimilar market brought by the GSAV law which plans biosimilar substitution in pharmacies for 2022.
Topics include presentations of the current system of biosimilar quotas, discount contracts and capped reimbursement and their impact on launch strategy.
Speakers include representatives of HTA body G-BA, payers, doctors' associations, consultancy firm IQVIA and lawmakers.
Ask for a Free trial and get access to the latest stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.